Haemonetics (NYSE:HAE) Given New $145.00 Price Target at Barrington Research

Haemonetics (NYSE:HAE) had its target price increased by Barrington Research from $140.00 to $145.00 in a research report released on Friday,Benzinga reports. The firm currently has an outperform rating on the medical instruments supplier’s stock.

A number of other research firms have also commented on HAE. JPMorgan Chase & Co. raised their price objective on shares of Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Raymond James Financial upped their target price on shares of Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, September 3rd. Citigroup lifted their target price on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Mizuho set a $165.00 price target on Haemonetics in a report on Thursday. Finally, BTIG Research upped their target price on shares of Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $126.38.

Haemonetics Stock Performance

Haemonetics stock traded down $4.24 during mid-day trading on Friday, hitting $119.87. 834,665 shares of the company’s stock traded hands, compared to its average volume of 762,819. Haemonetics has a one year low of $51.00 and a one year high of $132.00. The firm has a 50 day moving average price of $111.48 and a 200 day moving average price of $80.05. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The company has a market cap of $5.45 billion, a PE ratio of 53.75, a price-to-earnings-growth ratio of 2.40 and a beta of 0.63.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. The firm had revenue of $357.76 million during the quarter, compared to analyst estimates of $345.15 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. Haemonetics’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.27 EPS. On average, equities analysts forecast that Haemonetics will post 5.29 EPS for the current year.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in Haemonetics during the second quarter worth about $33,326,000. Assenagon Asset Management S.A. increased its holdings in shares of Haemonetics by 1,191.9% during the third quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock worth $47,762,000 after buying an additional 418,470 shares in the last quarter. William Blair Investment Management LLC bought a new position in shares of Haemonetics in the 2nd quarter valued at $24,906,000. Bank of New York Mellon Corp bought a new position in shares of Haemonetics in the 2nd quarter valued at $21,566,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Haemonetics by 21.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after acquiring an additional 233,119 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics News Roundup

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results beat expectations: Haemonetics earned $1.35 per share versus estimates of $1.29 and generated $357.8 million in revenue, above the $345.2 million consensus and up 9.4% year over year. Earnings and outlook report
• Positive Sentiment: Raised fiscal 2027 outlook: The company increased its full-year revenue and organic-growth outlook, forecasting organic growth of 6%–9%. Fiscal 2027 outlook
• Positive Sentiment: Analyst price targets rose: Citigroup raised its target to $149 and maintained a Buy rating; Barrington Research lifted its target to $145 with an Outperform rating; and BTIG raised its target to $142 with a Buy rating. Citigroup recommendations
• Neutral Sentiment: Growth comes with execution considerations: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027, and earnings-call coverage noted growth and margin tradeoffs. This may temper enthusiasm if rollout costs or margins disappoint. Earnings call highlights

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.